Atossa Therapeutics is advancing investigational (Z)-endoxifen as a biomarker-driven breast cancer treatment, aligning with the broader shift toward personalize

Atossa Therapeutics is advancing investigational (Z)-endoxifen as a biomarker-driven breast cancer treatment, aligning with the broader shift toward personalized oncology. The company says the effort builds on recent omics and organoid research.